Incidence and predictors of fragility fracture in postmenopausal rheumatoid arthritis patients receiving oral bisphosphonates: a longitudinal observational study

Table 2 Results of univariate and multivariate Cox proportional hazards analyses for fragility fractures in postmenopausal patients with rheumatoid arthritis receiving oral bisphosphonates

Variables	Univariable regression			Multivariable regression
Variables	HR	95% CI	P value	HR	95% CI	P value
Age	1.01	0.95–1.07	.661
BMI	0.96	0.82–1.14	.716
Disease duration	1.00	0.99–1.00	.117
History of vertebral fracture	5.67	2.17–14.79	< .001	6.26	1.99–19.68	.001
SDAI	0.98	0.92–1.04	.519
HAQ-DI	1.91	1.10–3.31	.020	1.34	0.74–2.45	.325
Rheumatoid factor positive	2.51	0.81–7.07	.107
Rheumatoid factor titer	1.00	0.99–1.00	.900
ACPA positive	1.76	0.57–5.40	.323
ACPA titer	1.00	0.99–1.00	.398
CRP	1.12	0.71–1.75	.621
Concomitant oral glucocorticoid	2.52	1.00–6.37	.049	2.02	0.70–5.81	.190
Dose of oral glucocorticoid	1.10	0.93–1.29	.255
Concomitant methotrexate	0.34	0.11–1.05	.061
Dose of methotrexate	0.82	0.73–0.92	< .001	0.87	0.76–0.99	.041
Concomitant bDMARDs	1.61	0.65–3.98	.297
Lumbar BMD	0.48	0.00–28.29	.724
Total hip BMD	0.01	0.00–3.19	.104
Vitamin D supplementation	0.56	0.16–1.96	.371
Minodronate	0.56	0.18–1.64	.303
Risedronate	0.70	0.21–2.36	.575

HR, Hazard ratio; 95% CI, 95% confidence interval; BMI, body mass index; SDAI, Simplified Disease Activity Index; HAQ-DI, Health Assessment Questionnaire Disability Index; ACPA, anticyclic citrullinated protein antibodies; CRP, C-reactive protein; bDMARDs, biological disease-modifying antirheumatic drugs; BMD, bone mineral density; BP, bisphosphonates

ISSN: 2520-1026